# GLOW Stack dosage guide

> Compare GLOW Stack component doses, administration routes, schedules and safety information.

Canonical: https://pepflow.app/stacks/glow-stack/dosage/

Compare the doses and schedules of BPC-157, TB-500, GHK-Cu and calculate each component separately.

[Full GLOW Stack library reference](<https://pepflow.app/stacks/glow-stack/>)

## GLOW Stack dosage chart

This summary compares component doses by route. These are separate component amounts, not a combined blend dose.

| Component / route | Dose | Frequency & duration |
| --- | --- | --- |
| [BPC-157](<https://pepflow.app/peptides/bpc-157/dosage/>) · Injectable | 250–500 mcg | 1–2x daily · 4–8 wk |
| [BPC-157](<https://pepflow.app/peptides/bpc-157/dosage/>) · Oral | 3 mg | 3 times daily · 14 days |
| [BPC-157](<https://pepflow.app/peptides/bpc-157/dosage/>) · Topical | 1 mcg/g cream (mouse experiment) | Once daily · Observations through 21 days |
| [TB-500](<https://pepflow.app/peptides/tb-500/dosage/>) · Injectable | 2–4 mg | 2-3 times weekly · 4-8 weeks |
| [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/dosage/>) · Topical | 1–3% | 1–2x daily · 8–12 wk |
| [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/dosage/>) · Injectable | 1–2 mg | 1-2 times daily · 4-12 weeks |
| [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/dosage/>) · Transdermal | 2 mL of 5.8 mM (GHK)₂Cu donor solution | Single laboratory exposure · 9-hour human-skin experiment |

## GLOW Stack dosage by administration route

### BPC-157 · Injectable

Commonly reported injection protocols use 250–500 mcg per dose, 1–2x daily, for 4–8 wk. Once-daily schedules use one administration; twice-daily schedules separate morning and evening administrations. An alternative reported subcutaneous schedule uses 200 mcg daily in weeks 1–2, 400 mcg daily in weeks 3–4, and 600 mcg daily from week 5. An alternative schedule uses an 8–16-week course; this is separate from the fixed-dose pattern above.[\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[44\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-44>) [\[13\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-13>) [\[14\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-14>) [\[41\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-41>)

Subcutaneous BPC-157 is given beneath the skin. BPC-157 may support tendon, muscle and ligament repair.[\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[44\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-44>) [\[13\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-13>) [\[14\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-14>)

### BPC-157 · Oral tablets

For the oral tablet formulation, the documented schedule is 3 mg every eight hours (3 times daily) for 14 days, totaling 9 mg per day.[\[18\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-18>) [\[19\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-19>)

Oral BPC-157 may support protection and repair of the stomach and intestinal lining.[\[18\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-18>) [\[19\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-19>)

### BPC-157 · Topical — experimental mouse cream

The experimental burn-wound cream contains 1 mcg of BPC-157 per gram and is applied once daily, with observations through 21 days. This mouse preparation specifies a concentration, not a quantified amount of cream per application or a human topical regimen.[\[21\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-21>) [\[1\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-1>)

Topical BPC-157 may support local skin and wound repair.[\[21\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-21>) [\[1\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-1>)

### TB-500 · Injectable

Reported injectable protocols use 2–4 mg per administration, 2-3 times weekly for 4-8 weeks. A separate reported daily subcutaneous pattern uses 500 mcg in weeks 1–2, 600 mcg in weeks 3–4, 750 mcg in weeks 5–8, then 1 mg in weeks 9–12. Its daily microgram amounts are distinct from a milligram amount given two or three times weekly.[\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[42\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-42>)

TB-500 is the N-acetylated LKKTETQ fragment associated with thymosin beta-4 biology. Its proposed role concerns cell movement and soft-tissue remodeling; benefits from the fragment are not interchangeable with those of full-length thymosin beta-4.[\[24\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-24>) [\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[25\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-25>) [\[4\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-4>)

### GHK-Cu · Topical

Reported topical GHK-Cu routines use 1–3% formulations applied once or twice daily for 8–12 weeks.[\[39\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-39>)

GHK-Cu is a copper-binding signal peptide involved in collagen and extracellular-matrix turnover. Topical formulations may support skin texture and appearance.[\[23\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-23>) [\[31\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-31>) [\[32\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-32>) [\[9\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-9>) [\[6\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-6>) [\[8\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-8>) [\[33\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-33>) [\[34\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-34>) [\[39\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-39>)

### GHK-Cu · Injectable

Reported injectable protocols use 1–2 mg per administration, 1-2 times daily for 4-12 weeks. An alternative reported subcutaneous schedule steps from 1 mg in weeks 1–4 to 1.5 mg in weeks 5–8 and 2 mg from week 9, on three or five days per week, over 8–12 weeks.[\[31\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-31>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[7\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-7>) [\[40\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-40>)

Injectable GHK-Cu produces systemic exposure to a copper-binding peptide. The skin-appearance findings for topical cosmetics do not establish the effects of systemic administration.[\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[6\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-6>) [\[8\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-8>) [\[33\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-33>) [\[31\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-31>) [\[34\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-34>)

### GHK-Cu · Transdermal — ex vivo microneedles

The microneedle experiment places 2 mL of 5.8 mM (GHK)₂Cu solution over a 1 cm² excised-skin sample, with human-skin permeation measured over 9 hours. The starting complex has a 2:1 GHK-to-copper molar ratio. This is the donor solution placed above the skin, not the amount absorbed or a patient patch dose.[\[35\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-35>)

Transdermal GHK-Cu depends on its carrier and delivery system. A consistent absorbed amount or systemic treatment effect has not been established for these preparations.[\[35\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-35>) [\[6\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-6>) [\[8\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-8>) [\[33\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-33>) [\[31\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-31>) [\[34\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-34>)

### Frequency and timing

**BPC-157:** Once-daily schedules use a morning or evening administration; twice-daily schedules separate morning and evening administrations. The oral tablet schedule uses an eight-hour interval.[\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[44\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-44>) [\[13\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-13>) [\[14\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-14>) [\[18\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-18>) [\[19\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-19>) [\[21\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-21>) [\[1\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-1>)

**TB-500:** Injections are commonly timed after a workout or in the evening.[\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>)

**GHK-Cu:** Topical products are applied in the morning or evening; injection timing follows a consistent morning or evening schedule. Experimental transdermal preparations follow their own application and observation periods.[\[7\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-7>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[39\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-39>) [\[31\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-31>) [\[35\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-35>)

### Cycle length and breaks

**BPC-157:** Injectable courses run 4–8 weeks. Reported clinic protocols include a 2–4-week break between injectable courses; long-term safety remains unknown, including with cycling. The oral tablet schedule spans 14 days.[\[45\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-45>) [\[43\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-43>) [\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[18\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-18>) [\[19\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-19>)

**TB-500:** Injectable: 4-8 weeks. A standard break interval between courses is not established.[\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>)

**GHK-Cu:** Topical: 8–12 wk. Injectable: 4-12 weeks. Transdermal — ex vivo microneedles: 9-hour human-skin experiment. A standard break interval between courses is not established.[\[39\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-39>) [\[31\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-31>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[7\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-7>) [\[35\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-35>)

## GLOW Stack dosage calculator

Calculate each separately prepared component using its own vial strength and final volume. A fixed-ratio blend requires the amount of every component; the total blend weight alone is insufficient.

See the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>) for preparation terms. For the distinction between separate preparations and mixed vials, read the [mixing versus co-scheduling explainer](<https://pepflow.app/blog/can-you-mix-peptides-together/>).

## GLOW Stack safety and side effects

### Combination and product quality

GLOW has no validated combined treatment dose. Topical GHK-Cu and injectable GHK-Cu have different exposure and safety considerations. A fixed-ratio blend prevents independent adjustment of BPC-157, TB-500 and GHK-Cu; irritation, injection-site reactions and copper exposure require separate attention.[\[7\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-7>) [\[9\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-9>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[12\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-12>)

### Side effects and long-term safety

**BPC-157:** Route-specific pharmacokinetics, dose-ranging, long-term safety, interactions, safety in special populations, product purity and human recovery outcomes remain unresolved. Small human reports have not shown a clear adverse-event pattern. FDA identifies compounding concerns involving immunogenicity for certain routes, peptide-related impurities and active-ingredient characterization; sports-medicine reviews also warn about unapproved peptide-market risks.[\[18\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-18>) [\[15\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-15>) [\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[16\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-16>) [\[2\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-2>)

**TB-500:** Local injection-site irritation is a practical concern, while fragment-specific systemic adverse-event rates remain unresolved. Pharmacokinetics, long-term safety, human recovery outcomes and whether commercial products match the material described remain uncertain. FDA has not identified human exposure data for drug products containing TB-500.[\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[24\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-24>) [\[26\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-26>) [\[27\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-27>)

**GHK-Cu:** For topical GHK-Cu, local irritation, stinging, redness, itching and sensitivity are the main tolerability concerns. Vehicle, pH, delivery method, copper loading and peptide content can change tolerability and performance. Injectable or systemic exposure adds concerns about aggregation, impurities, immunogenicity and product quality. Long-term injectable safety, human dose-ranging and route-specific interactions remain uncertain.[\[7\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-7>) [\[35\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-35>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[32\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-32>) [\[23\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-23>) [\[9\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-9>) [\[36\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-36>)

### Route-specific dosing limits

Separate products and fixed-ratio blends have different preparation requirements. Keep the exact formulation, component amount and route with each recorded dose.

## Peptides in GLOW Stack

Open each full dosage guide for its routes, schedules and references.

[**BPC-157 dosage** A stable gastric pentadecapeptide represented by GEPPPGKPADDAGLV, best known for gut and soft-tissue repair biology across tendon, ligament, muscle, wound, vascular, and gastrointestinal repair biology.](<https://pepflow.app/peptides/bpc-157/dosage/>) [**TB-500 dosage** A synthetic N-acetylated LKKTETQ fragment associated with thymosin beta-4 repair biology, best known in peptide-market use for soft-tissue recovery claims but supported mainly by thymosin beta-4 mechanism, local wound and eye research, anti-doping detection work, and limited direct TB-500 human research activity.](<https://pepflow.app/peptides/tb-500/dosage/>) [**GHK-Cu dosage** The most-studied copper peptide in skincare: a naturally occurring tripeptide (GHK, Gly-His-Lys) whose best-known tissue form is the copper complex GHK-Cu, with extensive research supporting skin remodeling, collagen synthesis, wound-repair biology, and skin-aging applications.](<https://pepflow.app/peptides/ghk-cu/dosage/>)

[All peptide and stack dosage guides →](<https://pepflow.app/peptide-dosage/>)

## Common GLOW Stack dosage questions

### Does GLOW Stack have one combined dose?

Each component has its own amount and schedule. A stack name does not define a blend ratio or combined dose.

### Can the component doses be calculated separately?

Yes, for separately prepared components. Use each vial's peptide amount and final volume in the calculator. A combined vial requires its exact component composition.

### Does topical GHK-Cu use the same dose as injectable GHK-Cu?

No. Topical GHK-Cu has a local formulation concentration and application amount. An injectable amount does not define how much cream to apply or its concentration.[\[1\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-1>) [\[2\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-2>) [\[3\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-3>) [\[4\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-4>) [\[5\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-5>) [\[6\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-6>) [\[7\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-7>) [\[8\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-8>) [\[9\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-9>) [\[10\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-10>) [\[11\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-11>) [\[12\]](<https://pepflow.app/stacks/glow-stack/dosage/#source-12>)

## Sources

- [\[1\] **Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.** PubMed / Frontiers in Pharmacology, 2021. review.](<https://pubmed.ncbi.nlm.nih.gov/34267654/>)
- [\[2\] **Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.** PubMed / HSS Journal, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40756949/>)
- [\[3\] **The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.** PubMed / Journal of Applied Physiology, 2011. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/21030672/>)
- [\[4\] **Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications.** PubMed / Expert Opinion on Biological Therapy, 2012-01. review.](<https://pubmed.ncbi.nlm.nih.gov/22074294/>)
- [\[5\] **Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.** PMC / Clinical Ophthalmology, 2007. review.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>)
- [\[6\] **GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.** PubMed / BioMed Research International, 2015. review.](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)
- [\[7\] **Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.** PubMed / Archives of Facial Plastic Surgery, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16847171/>)
- [\[8\] **Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.** PubMed / FEBS Letters, 1988. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/3169264/>)
- [\[9\] **Topical GHK-Cu Gel for Acute Skin Wound Healing** ClinicalTrials.gov, 2026. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07437586>)
- [\[10\] **Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.** PubMed / Sports Medicine, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- [\[11\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[12\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[13\] **Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.** PubMed / Journal of Physiology and Pharmacology, 2009. animal.](<https://pubmed.ncbi.nlm.nih.gov/20388964/>)
- [\[14\] **Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.** PubMed / Journal of Orthopaedic Research, 2010. animal.](<https://pubmed.ncbi.nlm.nih.gov/20225319/>)
- [\[15\] **BPC 157 for Acute Hamstring Muscle Strain Repair** ClinicalTrials.gov, 2026. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07437547>)
- [\[16\] **Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.** PubMed / Alternative Therapies in Health and Medicine, 2025. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40131143/>)
- [\[17\] **Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.** PubMed / Alternative Therapies in Health and Medicine, 2021. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34324435/>)
- [\[18\] **PCO-02 - Safety and Pharmacokinetics Trial** ClinicalTrials.gov, 2015. clinical trial registry.](<https://clinicaltrials.gov/study/NCT02637284>)
- [\[19\] **Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.** PubMed / Current Pharmaceutical Design, 2011. review.](<https://pubmed.ncbi.nlm.nih.gov/21548867/>)
- [\[20\] **Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.** PubMed / Current Medicinal Chemistry, 2012. review.](<https://pubmed.ncbi.nlm.nih.gov/22300085/>)
- [\[21\] **Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice.** PubMed / Burns, 2001. animal.](<https://pubmed.ncbi.nlm.nih.gov/11718984/>)
- [\[22\] **Search Drugs@FDA for BPC-157 names** U.S. Food and Drug Administration / openFDA. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[23\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[24\] **TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD** ClinicalTrials.gov, 2026. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07487363>)
- [\[25\] **Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry.** PubMed / Journal of Chromatography A, 2012-11-23. animal.](<https://pubmed.ncbi.nlm.nih.gov/23084823/>)
- [\[26\] **A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers.** PubMed / Journal of Cellular and Molecular Medicine, 2021-09. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34346165/>)
- [\[27\] **A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.** PubMed / Annals of the New York Academy of Sciences, 2010-04. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/20536472/>)
- [\[28\] **Search Drugs@FDA for TB-500 and thymosin beta-4** openFDA / U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[29\] **Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye** ClinicalTrials.gov, 2012. clinical trial registry.](<https://clinicaltrials.gov/study/NCT01393132>)
- [\[30\] **Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers** ClinicalTrials.gov, 2009. clinical trial registry.](<https://clinicaltrials.gov/study/NCT00832091>)
- [\[31\] **Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.** PubMed / BioImpacts, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39963574/>)
- [\[32\] **Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?** PubMed / Molecules, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/39795193/>)
- [\[33\] **The human tri-peptide GHK and tissue remodeling.** PubMed / Journal of Biomaterials Science, Polymer Edition, 2008. review.](<https://pubmed.ncbi.nlm.nih.gov/18644225/>)
- [\[34\] **GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis.** PubMed / Wound Repair and Regeneration, 2017. animal.](<https://pubmed.ncbi.nlm.nih.gov/28370978/>)
- [\[35\] **Microneedle-Mediated Delivery of Copper Peptide Through Skin.** PubMed / Pharmaceutical Research, 2015. ex vivo.](<https://pubmed.ncbi.nlm.nih.gov/25690343/>)
- [\[36\] **Wilson Disease** MedlinePlus / National Library of Medicine. official guidance.](<https://medlineplus.gov/wilsondisease.html>)
- [\[37\] **Orange Book Data Files** U.S. Food and Drug Administration, 2026-05-08. database query.](<https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files>)
- [\[38\] **Search Drugs@FDA for GHK-Cu names** U.S. Food and Drug Administration / openFDA. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[39\] **PepFlow peptide cheat sheet — reported-use and product-orientation reference (not clinical research)** PepFlow. reference catalog.](<https://pepflow.app/peptide-cheat-sheet/>)
- [\[40\] **GHK-Cu — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-ghk-cu.html>)
- [\[41\] **BPC-157 — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-bpc-157.html>)
- [\[42\] **TB-500 — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-tb-500.html>)
- [\[43\] **FDA evaluation of BPC-157 (free base) and BPC-157 acetate** U.S. Food and Drug Administration. regulatory evaluation.](<https://www.fda.gov/media/193343/download>)
- [\[44\] **Subcutaneous (SQ) injections** MedlinePlus / U.S. National Library of Medicine, 2025-10-19. patient education.](<https://medlineplus.gov/ency/patientinstructions/000430.htm>)
- [\[45\] **BPC-157 Dosage: A Complete Guide — reported clinic cycle breaks** Dr. Rogers Centers, 2026-03-13. clinic protocol report.](<https://drrogerscenters.com/blogs/news/bpc-157-dosage-a-complete-guide>)

[Full GLOW Stack library reference →](<https://pepflow.app/stacks/glow-stack/>)

## Related

- [GLOW Stack](<https://pepflow.app/stacks/glow-stack/>)
- [BPC-157 Dosage Chart, Schedules & Calculator](<https://pepflow.app/peptides/bpc-157/dosage/>)
- [TB-500 dosage guide](<https://pepflow.app/peptides/tb-500/dosage/>)
- [GHK-Cu dosage guide](<https://pepflow.app/peptides/ghk-cu/dosage/>)
